Calcium oxalate crystal deposition reduction

Calcium oxalate crystal deposition reduction is a therapeutic objective and clinical endpoint rather than a single molecular target. It refers to the physiological process of preventing the formation and accumulation of insoluble calcium oxalate crystals in the renal parenchyma and systemic tissues, a condition that leads to progressive organ damage in patients with hyperoxaluria [1][2]. This objective is typically met by targeting specific hepatic enzymes involved in the glyoxylate metabolic pathway, such as glycolate oxidase (HAO1) or lactate dehydrogenase (LDH), to decrease the overproduction of oxalate [3]. Drugs such as Lumasiran and Nedosiran utilize RNA interference technology to silence these metabolic precursors, thereby lowering the oxalate burden and reducing the risk of nephrocalcinosis and end-stage renal disease [4][5]. Effectively reducing crystal deposition is the primary strategy for managing Primary Hyperoxaluria (PH) and preserving long-term kidney function [2]. Sources: [1] PubMed: 31057038 (Review on Oxalate and Kidney Stone Disease) [2] GeneReviews: Primary Hyperoxaluria Type 1 (Clinical management and pathology) [3] NIH/PubChem: Lumasiran and Nedosiran pharmacology profiles [4] FDA: Oxlumo (Lumasiran) Prescribing Information [5] The Lancet: Nedosiran in Primary Hyperoxaluria (PHYOX2 clinical trial results)

Other names

Inhibition of calcium oxalate crystallizationReduction of nephrocalcinosisPrevention of oxalate crystal formationOxalate reduction therapeutic effect

Reduction of hepatic oxalate production via RNA interference targeting glycolate oxidase (HAO1) or lactate dehydrogenase (LDH), or through enzymatic cofactor supplementation (Pyridoxine) to enhance glyoxylate metabolism.